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Abstract 
Background: Testing a hypothesis for ‘factors-outcome effect’ is a common quest, but standard statistical regression 
analysis tools are rendered ineffective by data contaminated with too many noisy variables. Expert Systems (ES) can 
provide an alternative methodology in analysing data to identify variables with the highest correlation to the out-
come. By applying their effective machine learning (ML) abilities, significant research time and costs can be saved. The 
study aims to systematically review the applications of ES in urological research and their methodological models for 
effective multi-variate analysis. Their domains, development and validity will be identified.
Methods: The PRISMA methodology was applied to formulate an effective method for data gathering and analysis. 
This study search included seven most relevant information sources: WEB OF SCIENCE, EMBASE, BIOSIS CITATION 
INDEX, SCOPUS, PUBMED, Google Scholar and MEDLINE. Eligible articles were included if they applied one of the 
known ML models for a clear urological research question involving multivariate analysis. Only articles with pertinent 
research methods in ES models were included. The analysed data included the system model, applications, input/
output variables, target user, validation, and outcomes. Both ML models and the variable analysis were comparatively 
reported for each system.
Results: The search identified n = 1087 articles from all databases and n = 712 were eligible for examination against 
inclusion criteria. A total of 168 systems were finally included and systematically analysed demonstrating a recent 
increase in uptake of ES in academic urology in particular artificial neural networks with 31 systems. Most of the 
systems were applied in urological oncology (prostate cancer = 15, bladder cancer = 13) where diagnostic, prognos-
tic and survival predictor markers were investigated. Due to the heterogeneity of models and their statistical tests, a 
meta-analysis was not feasible.
Conclusion: ES utility offers an effective ML potential and their applications in research have demonstrated a valid 
model for multi-variate analysis. The complexity of their development can challenge their uptake in urological clinics 
whilst the limitation of the statistical tools in this domain has created a gap for further research studies. Integration of 
computer scientists in academic units has promoted the use of ES in clinical urological research.
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to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory 
regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this 
licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/. The Creative Commons Public Domain Dedication waiver (http:// creat iveco 
mmons. org/ publi cdoma in/ zero/1. 0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction
In the 1950’s J McCarthy in Stanford University and A 
Turing in Cambridge University proposed the concept of 
machine simulation of human learning and intelligence 
[1, 2]. Being keen mathematicians, they advanced the 
basic mathematical logic into programming languages 
enabling machines to perform more complex functions. 
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E Shortliffe advanced those systems to develop MYCIN, 
which successfully simulated the reasoning of a human 
microbiologist in diagnosing and treating patients with 
microbial infection [3]. Their model introduced Expert 
Systems (ES) to the scientific literature and a ten year 
review by Liao et  al. demonstrated their wide preva-
lence in the industrial fields with immense applications 
including health care [4]. In contrast to Liao’s review, 
other studies questioned their real time implementation 
in health care and suggested a lack of their uptake and 
integration in the health care systems [5]. This is despite 
evidence from systematic reviews demonstrating the 
positive impact of computer aid systems on patients’ out-
come and health care [6, 7].
This study aimed to systematically review published 
ES in urological health care with a primary aim to dem-
onstrate their availability, progression, testing and 
applications. The secondary aim was to evaluate their 
development life cycle against standards suggested by 
O’Keefe and Benbasat in their review articles on ES 
development [8, 9]. The later would evaluate the gap 
between their development and implementation in 
health care.
Methods
The study methodology followed the recommendations 
outlined in the Preferred Reporting Items for System-
atic Reviews and Meta-Analyses (PRISMA) statement 
(Fig.  1). No ethical approval was required because the 
type of the study waives this requirement.
Search
Information sources including WEB OF SCIENCE, 
EMBASE, BIOSIS CITATION INDEX, SCOPUS, PUB-
MED, Google Scholar and MEDLINE were searched 
using key words in (Table 1). Articles published between 
1960 and 2016 were considered and examined against the 
inclusion criteria. While tailoring the conducted search 
for each literature database, the key words were com-
bined by “OR” in each domain, then domains were com-
bined by “AND”.
Fig. 1 PRISMA flow chart for the systematic review of articles included in the review of expert systems in urology
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Eligibility criteria
For the primary aim, data search was conducted to yield 
the collected results then analyse them according to pre-
planned eligibility criteria based on the system model, 
year of production, type and outcome of its validation, 
functional domain application, variables for input and 
output, target user and domain. This selection criteria 
were designed with an objective to identify expert system 
studies and demonstrate their prevalence, testing, and 
applications in clinical urology. Only articles and studies 
written in English were included.
Further qualitative analysis was required to meet the 
study secondary aim. For this, further data was gathered 
on credibility (user perception on the system), evaluation 
(system usability), validation (building the right system) 
and verification (building the system right) then compare 
against the standards reported in [8, 9].
Data filtering
The resultant reference list of each included article was 
checked to identify a potentially eligible item that had 
not been retrieved by the initial search. All retrieved arti-
cles were collated in a final reference list on a manage-
ment software (Endnote, X8), then duplicate studies were 
removed from the list.
Upon including more than one hundred articles, the 
rest of the eligible articles were meticulously compared to 
the ones included, then excluded based on demonstrat-
ing clear similarity. This was applied to avoid expanding 
the size of the data without adding to the study analysis.
Results
ANN was the commonest model to be applied in Uro-
logical ES (Fig. 2). The rest of the models demonstrated 
diversity which is consistent with other published indus-
trial systems [4].
Prostate cancer was the commonest domain for urolog-
ical ES with most of the system focusing on cancer diag-
nosis. These systems were applied to various domains 
(Fig.  3), and they were further stratified and analysed 
according to their core functional application as outlines 
in the methodology.
Table 1 Keywords used for literature search
#1 TOPIC: ("expert system*") OR TOPIC: ("decision support") OR TOPIC: ("artifi-
cial intelligence") OR TOPIC: ("rule based") OR TOPIC: ("knowledge base* 
system*") OR TOPIC: ("neural network") OR TOPIC: ("fuzzy")
DocType = All document types; Language = All languages;
#2 TOPIC: (urology)
DocType = All document types; Language = All languages;
#3 #1 AND #2
DocType = All document types; Language = All languages;
Analysis of Expert Systems (ES) by Models
126
13 9 8 5 3 3 1 1
ANN FNM RBS FRB SVM HYBRID 
FUZZY










Fig. 2 Analysis of Expert Systems (ES) by models (n = 169). ANN was the most common but other systems were applied on different domain as 
fuzzy neural model (FNM), rule-based system (RBS), fuzzy rule based (FRB), support vector machine (SVT), Bayesian network (BN) and decision trees 
(DT)
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Quantitative analysis
Decision support systems
The main objective of ES in this domain was to facilitate 
the clinical decision making by identifying key elements 
from patients clinical and laboratory examinations then 
refine a theoretical diagnostic or treatment strategy [10]. 
They can guide the expert to find the right answer [11] or 
take over the decision making to support the none expert 
as [12] or even replace both to interact with the patient 
directly [13].
They have supported various aspects of urological deci-
sion making such as diagnosis, investigations analysis, 
radiotherapy dose calculation, the delivery of behavioural 
treatment and therapeutic dialogues.
Domains Urinary dysfunction (U Dys) was the com-
monest domain to be covered in the decision support 
system application (n = 9), which could be further cate-
gorised into U Dys diagnostic, investigation analysis and 
therapeutic systems. They have demonstrated a range of 
methodologies, validation, and target users (Table  2) 
applicable to Decision support systems in Urological 
domain. For instance, Keles et al. [14] designed an ES to 
support junior nurses in diagnosing urinary elimination 
dysfunction in a selected group of patients while [15, 16] 
systems were able to support any medical user to diag-
nose urinary incontinence with an accuracy reaching 
higher than 90%. The target user of most of these sys-
tems were predominantly medical health care workers 
including both experts and none experts, with excep-
tion of [13, 17] which can be directly used by patients to 
receive an assessment of their urinary elimination dys-
function followed by a tailored treatment plan.
Prostate diseases were represented in 6 systems while 
3 of them modelled by [10, 12, 20] for diagnosing both 
benign and malignant prostatic disease, namely cancer 
prostate (CaP).
All systems in this domain were diagnosis support 
system with exception of [19] which also provided 
treatment for benign prostatic hyperplasia (BPH) and 
[11] calculated the required radiotherapy dose for 
treating CaP.
Sexual dysfunctions were modelled in 3 systems where 
[21] diagnosed male sexual dysfunction with an accuracy 
of 89%, while [22] added a therapeutic model for the same 
disease with an overall accuracy of 79%. Sexpert by [23] 
was the third system in this category developed in 1988 
and in fact the oldest ES to be identified from our search 
in all urological domains. Interestingly this RB system 
was designed to interact directly with couples suffering 
from sexual dysfunction where the system responds to 
their query with a tailored therapeutic dialogue for treat-
ing their problem.
Urinary tract infection (UTI) was diagnosed and 
treated by one of the hybrid fuzzy systems FNM devel-
oped by [24] with an accuracy of 86.8%.
91
31
11 9 7 6 3 2 2 2 1 1 1 1
Urological domains
Fig. 3 Urological domains (n = 168) applied by Expert Systems (ES). Prostate cancer (CaP) was the commonest domain followed by bladder cancer 
(Bca) then other diseases as benign prostatic disease (BPD), pelvi ureteric junction obstruction (PUJ), urinary tract infection (UTI), renal cell cancer 
(RCC), vesico ureteric reflux (VU reflux)
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Diagnosis prediction
In this domain, ES quantifying the probability of a clinical 
diagnosis with a defined margin of error. They simulate 
a second expert opinion and it has been suggested that 
their use could eliminate unnecessary invasive investiga-
tion as the application of ANN by [26] could reduce up to 
68% of repeated TRUS biopsies to diagnose CaP.
Domains Prostate cancer was the main domain for this 
application with 19 systems out of 20. Most of them were 
designed to predict organ confinement before radical 
surgical excision of the prostate (Tables 3, 4). The target 
population were patients with clinically localised CaP and 
their accuracy reached high estimates as in [28], where 
the system was able to predict 98% of the low risk group 
for lymph node involvement using preoperative available 
date (PSA, clinical stage and Gleason score).
Chiu et  al. [29] modelled a system with clinical vari-
ables for patients undergoing nuclear bone scintigraphy 
for predicting skeletal metastasis. The system was able 
to predict metastatic disease in the test group with Se 
87.5%, Sp 83.3%.
None seminoma testicular cancer was the other domain 
in this application with the system [27] able to predict 
the cancer disease stage (Table 4) with accuracy reaching 
87%.
Treatment outcome prediction
In this application, ES combined disease and patient 
related factors to estimate the success of a specific treat-
ment or intervention. As in [30, 38, 64, 69] where the sys-
tem predicted the outcome of extra corporeal shock wave 
(ESWL) for treating kidney stones and [74, 75] providing 
an estimation of cancer recurrence after radical surgical 
treatment of prostate cancer.
Domains Prostate cancer was also common domain 
in this application (n = 23). Potter [74, 75] described 4 
models developed by data acquired from patients with 
clinically localised CaP and had radical prostatectomy 
with curative intent. The variables included clinical and 
histological findings of the surgical specimen and they 
were able to predict up to 81% who did not have evidence 
biochemical failure (rising PSA) in their follow up. Hamid 
et al. [76] and Gomha [77] models were not restricted to 
the clinically localised CaP cohort and their study popula-
tion included patients at different disease stages and on 
any treatment pathway. Their models included 2 experi-
mental histological markers (tumour suppressor gene p53 
and the proto-oncogene bcl-2) in their input variables and 
the estimated predictive accuracy of the patient response 
to treatment were reaching 68% and 80% (p < 0.00001) 
respectively.
Nephrolithiasis treatment was expressed by 6 other 
systems applying the treatment outcome prediction con-
cept. Cummings et  al. targeted this group in his ANN 
[78] where he trained his network with patients’ data 
treated at the emergency service of 3 centres with ure-
teric stones, to identify patients failing conservative man-
agement and requiring further intervention. When tested 
on a different set of 55 cases, the system correctly pre-
dicted 100% of the patients who passed the stone sponta-
neously with an overall accuracy of 76%.
Extra corporeal shockwave lithotripsy (ESWL) is one 
of the favourable interventions in the nephrolithiasis 
treatment domain. The stone here receives strong exter-
nal shock waves, which can subsequently reduce it into 
small fragment and eliminate the need for direct instru-
mentation of the renal tract. Their reported success rate 
can only provide a generalised prediction of outcome to 
the individual case and ANN was capable of providing 
an alternative multivariate analytical tool in the 4 mod-
els developed by [30, 38, 64, 69]. They estimated high 
accuracy of their models (Table 5), as in [64], the system 
predicted 97% of the patients who were confirmed to be 
stone free following ESWL for treating ureteric stone.
Paediatric pelvi-ureteric junction obstruction is primar-
ily treated conservatively unless there is any evidence of 
renal function compromise, recurring infection or wors-
ening radiological findings. For the failing group, pyelo-
plasty is the second line of treatment and [81] developed 
an ANN to estimate the success rate of this procedure 
for each individual case by predicting the post-operative 
degree of hydronephrosis with a reported 100% accuracy 
in the small tested sample.
Vesico ureteric reflux or reflux uropathy is another pae-
diatric disease, characterised by back flow of urine from 
the bladder into the ureter through incompetent Vesico 
ureteric functional valve. Treatment is primarily con-
servative as it can be a self-limiting disease or surgery 
to reimplantation the ureters or endoscopic injection 
of bulking agent at the ureteric orifices [80]. The study 
authors trained a neural network using 261 cases whom 
have received endoscopic injection and the system pre-
dicted 94% of the patients who did not benefit from the 
treatment [80].
Laparoscopic partial and radical nephrectomy were 
the domain of the [82], which was developed by multi 
institutional case data (age, co-morbidities, tumour size, 
and extension) of patients having laparoscopic partial or 
radical nephrectomy. The system was able to predict the 
length of their postoperative hospital stay with an accu-
racy of 72%.
Bladder cancer can be treated with complete bladder 
excision and [79] developed systems to predict the cure 
rate with an accuracy of 83%.
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Recurrence and survival prediction
The ES in this domain aimed to provide individualised 
risk analysis tools estimating the disease specific mortal-
ity and recognising the group whom may benefit from 
more aggressive or adjuvant treatment.
Domains Bladder cancer survival and recurrence pre-
diction following radical cystectomy (RC) with curative 
intention was the commonest domain in this application 
(24 out of 26 total systems). The lymph nodal involve-
ment is highly predictive of the recurrence and these 
patients are considered for adjuvant or neoadjuvant sys-
temic chemotherapy. The node free cohort will include 
high-risk patients who were not identified by the conven-
tional linear stratification system. Catto et al. developed a 
FNM system to identify this high risk group in the nodal 
free cohort by predicting the disease recurrence rate (Se 
81%, Sp 85%) and their survival with a median error of 
8.15 months [92]. The high-risk group identified by this 
model can benefit from systemic treatment post cystec-
tomy to improve their disease related morbidity and mor-
tality [95, 96]. The 5 years survival post cystectomy was 
the output of 2 other ANN with a high prediction efficacy 
of 77% and 90% respectively (Table 6) [97, 99].
Renal cell cancer is primarily treated with partial or 
radical nephrectomy for clinically localised disease with 
systemic therapy for the metastatic disease. There is still 
a degree of uncertainty in stratifying individual disease 
risk in order to predict the indication and outcome of 
systemic therapy in the group with distant metastasis. 
Vukicevic et al. [98] attempted to clarify this uncertainty 
by training a neural network with patients’ data who had 
nephrectomy (partial or radical) and received systemic 
therapy. The mature model predicted the patients who 
survived the disease at 3 years with an overall accuracy of 
95% (CI 0.878–0.987).
None seminoma testicular cancer 5  years recurrence 
was the domain of [118] ANN. The system was trained 
with multicentre data and in its testing phase and pre-
dicted 100% of the patients who did not suffer from 
disease recurrence at 5  years with an overall predictive 
accuracy of 94% (AUC = 87%).
Predicting research variables
In academia, testing a hypothesis for ‘factors-outcome 
effect’ is a popular quest and the standard statistical 
regression analysis tools may not be effective for data 
contaminated by irrelevant variables [119]. AI can pro-
vide an alternative methodology in the analysis to iden-
tify variables with high correlation to the outcome by 
applying machine learning as in ANN. The area under the 
curve (AUC) is estimated for the system predictive accu-
racy applying all researched variables. Those research 
variables can be given random values or randomised then 
the AUC is re estimated for comparison with the origi-
nal [120]. Only variables that decreases the AUC are con-
sidered significant and the wider the discrepancy of the 
AUC the more significant they are (Table 7).
Domains Prostate cancer was a common domain in this 
application with a total of 15 systems analysing predictive 
factors for diagnosis of cancer, response to treatment and 
quality of life with prostatic disease. One of the hot topics 
in Urological cancer is discovering alternative CaP diag-
nostic markers since serum PSA is not sensitive for dis-
tinguishing benign from malignant disease. Stephan et al. 
investigated the diagnostic value of three markers in this 
domain: Macrophage inhibitory cytokine-1, macrophage 
inhibitory factor and human kallikrein 11 [108]. These 
were used as variables (nodes) in ANN models and com-
pared their accuracy to the linear regression of %fPSA. 
They have reported that only the ANN model including 
all three variables was more accurate (AUC 91%, Se 90%, 
Sp 80%) than all other models proving his hypothesis that 
they are only relevant as when combined.
Similarly, another study estimated the predictive val-
ues of serum PSA precursors (-5, -7 proPSA) in diagnos-
ing prostate cancer using and comparing the accuracy 
to %fPSA [107]. The -5, -7 pro PSA were only signifi-
cant in the cohort with PSA between 4 and10  µg/l and 
did not improve the predictive accuracy when added to 
the %fPSA. The same author tested this hypothesis on 
another free PSA precursor (-2 proPSA) by developing 
ANN with the %p2PSA (-2 ProPSA: fPSA) among other 
disease variables, which have improved the system accu-
racy (AUC 85% from 75%) [120].
Three systems evaluated the presence of bcl-2 and 
p53 (tumor suppressor genes) as a predictive variable 
for response to prostate cancer treatment [76, 77]. Their 
combination was reported to be significant (Ac 85%, 
p < 0.00001) in [77] but [76] found that only bcl-2 is rel-
evant in the other two models (accuracy 63–68%).
Bladder cancer diagnosis and disease progression 
was the second most common domain with 13 systems. 
Kolasa et  al. [110] have modeled an ANN with three 
novel urine markers: urine levels of nuclear matrix pro-
tein-22, monocyte chemoattractant protein-1 and uri-
nary intercellular adhesion molecule-1, to predict the 
diagnosis of bladder cancer and it succeeded in predict-
ing all cancer free patients when the three variables were 
used as a group. Catto.et al. [119] developed two AI mod-
els (ANN & FNM) performing microarray analysis on 
genes associated with bladder cancer progression. Their 
models narrowed down these genes from 200 to 11 pro-
gression-associated genes out of 200 ([OR] 0.70; 95% [CI] 
0.56–0.87), which were found to be more accurate than 
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the regression analysis when compared to the specimen 
immunohistology results.
Kolasa et  al. [110] model predicting the pre-histology 
diagnosis of malignancy based on urine level of novel 
tumour markers. Their ANN was found to be more accu-
rate (Se 100%, Sp 75.7%) than haematuria diagnosed on 
urine dipstick (Se 92.6%, Sp 51.8%) and atypical urine 
cytology (Se 66.7%, Sp 81%).
ESWL of renal stones was the research domain of [30, 
69], where they aimed at identifying significant vari-
ables correlated to the treatment outcome (stone free) 
and developing a predictive model. Chiu et al. [69] model 
did not recognise residual fragments following ESWL as 
a significant risk for triggering further stone growth and 
[30] identified these factor: positive BMI, infundibular 
width (IW) 5 mm, infundibular ureteropelvic angle 45% 
or more (IUPA), to be all predictive of lower pole stone 
breaking and clearance.
Benign prostatic hyperplasia was modelled in a system 
[114] to link the disease specific clinical and radiologi-
cal factors with the disease progression in patients with 
mild disease (IPSS < 7) and not receiving any treatment. 
His ANN identified: obstructive symptoms (Oss), PSA 
of more than 1.5 ng/ml and transitional zone volume of 
more than 25  cm3, to be correlated to disease progression 
and can accurately predict 78% of the cohort who will 
need further treatment.
Urinary dysfunction diagnosis accuracy by clini-
cal symptoms was compared to urodynamic findings in 
female patients with pelvic organ prolapse by [115] and 
both the linear regression and ANN models could not 
establish relation between the symptoms and urody-
namic based diagnosis hence dismissing the hypothesis 
of only relying on clinical symptoms to reach an accurate 
diagnosis and replace the need for urodynamics study.
Hypogonadism (Hgon) was represented in [133] sys-
tem where the diagnosis was made based on patient’s age, 
erectile dysfunction and depression with AUC of 70% 
(p < 0.01).
Image analysis
This one of the advancing applications of AI in medi-
cine where the system either analyse the variables in the 
reported medical images as data input or identifies these 
variables through a separate image analyser without the 
need for expert to report the scan or images. The first 
category was included among other systems mentioned 
above as in the diagnosis prediction domain where 
[47] included different variables from TRUS in the sys-
tem input to predict CaP diagnosis. In this domain, we 
focused on the other group where the images are pre-
sented to the machine in the form raw data translated by 
the image analyser and the system will then apply their 
machine learning to identify the cause effect pattern 
(Table 8).
Domains Prostate cancer image analysis was modelled 
in 10 systems to enhance diagnostic accuracy as in [126] 
and disease progression prediction as in [128]. The first 
system represented each TRUS image pixel as one vari-
able or neuron in a pulse coupled neural network and 
trained their system with 212 prostate cancer images to 
segment prostate gland boundary with an average overlap 
accuracy (overlap measure = difference between PCNN 
boundary and the expert) of 81% for ten images [126].
The other 4 systems analysed histological images of a 
cohort of patients post RP with clinically localised CaP to 
predict the disease progression. The histological images 
were given coloured coding and analysed by the system 
that used variables as % of epithelial cell and glandular 
Lumina to identify the high risk group for disease recur-
rence with an accuracy reaching 90% [128].
LUT disease urine cytology images were analysed by 2 
models in [123], which identified all patients with benign 
disease with an overall accuracy of 97%.
Nephrolithiasis stone biochemistry analysis can be 
achieved through an expert analysis of infrared spectros-
copy which was simulated by [124] where the infrared 
spectra wavelength numbers were modelled as input var-
iables and the system prediction accuracy of the expert 
analysed stone specimen had a root square mean error of 
3.471.
Qualitative analysis
The same articles were considered for the qualitative 
analysis against the four stages (validation, verification, 
evaluations and credibility) reported in Okeefe industrial 
survey [8] and Benbasat article [9]. The completion of 
the four stages examined in this qualitative analysis was 
demonstrated by none of the included systems. There is 
a possibility that some of these missing stages has been 
performed but not published in the scientific literature.
Validation was performed by almost all the systems 
(166 out 169) with varying degree of study strength, bias, 
and limitations (Table 9). Most of the data driven systems 
(ANN, SVM, BN, kNN and FNM) were validated by the 
ROC and AUC by having a training and validation set or 
cross validation or applying the leave one out technique. 
Samli et al. enhanced the validity of their system by esti-
mating the kappa statistics with the ROC [134].
Evaluation was only performed by a small fraction of 
these systems (n = 6). Their evaluation was aiming at the 
user or the expert but rarely both. There is no evidence 
to support that these were performed at early stages to 
determine the substantiality of the system to the user.
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System credibility and verification were never per-
formed. It would be implied that the verification was per-
formed to an extent but not reported as it is a technical 
part of the development.
‘System development limitation and bias evaluation’ 
demonstrated an overall acceptable validation meth-
odology with valid statistical analysis. However, a few 
observed limitations (Table  9) were reported with the 
common encounter being the consideration human 
opinion as a gold standard (n = 9). For instance, the gold 
standard in diagnosing prostate cancer is tissue biopsy 
confirmation. The interpretation of the expert clinical 
diagnosis as the gold standard reference can lead to sta-
tistical errors and invalidate the study.
Discussion
Expert Systems are widely available in Urological 
domains, with a large range of models, applications, 
domains, and target users including patients, students, 
non-experts, experts, and researchers. The number of 
published systems has risen over the years but with a 
consistent lack of publications reporting their real time 
testing or healthcare implementation (Fig. 4).
There is an increasing interest in analysing this gap 
which is reflected from the scope of AI historic review 
articles which aimed to only familiarise the readers 
with ES existence and application [33, 125]. In fact, the 
majority had a relatively narrow scope on the evolution 
and application of one ES models (artificial neural net-
work) in prostate cancer diagnosis. Recently, similar to 
our research, there has been more interest in AI valida-
tion, and lack of uptake despite the faith in their ability. 
Therefore, in this study we quantified ES progression 
and applications in Urology while examining their 
developmental life cycle.
It was evident that CaP was the commonest domain 
in almost all applications contributing with more than 
two thirds of the systems (91 systems in total). Dif-
ferent aspects of this domain have been simulated by 
these systems to include diagnosis, therapeutics, pre-
dictions of disease progression or treatment outcome, 
researching variables and medical images analysis. 
Most of these systems were simulating urologist cogni-
tive function with little guidance on their benefits and 
how they can be implemented to improve cancer deci-
sion making.
In industry, this is usually performed before the sys-
tem development by evaluating the system usability from 
the user perspective. This part has lacked or not been 
acknowledged in the published studies and is possibly a 
core reason for the lack of their integration in urological 
health care. Furthermore, none of these systems has been 
a subject to live testing in a well-designed study to prove 
its efficacy over standard tools or in the clinical context 
to prove its validity to justify their complex structure to 
AI novice health care professionals. The qualitative anal-
ysis demonstrated that validation is the only stage of the 
development cycle to be applied by most of the systems 
and there is a lack of system evaluation, credibility, and 
verification. The evaluation can be subdivided into usa-
bility (usually by average user), utility and system quality 
(by experts) [9]. Despite the crucial stage of ES develop-
ment, there has been a lack of attention in the published 
articles to integrate it into the development life cycle. 
This can mean the whole system can fail and also chal-
lenge its uptake [8].
An example can be drawn from this review where the 
majority of the systems  focused on CaP diagnosis and 
treatment. Their implementation would be challenged by 
the standard decision-making tools of the cancer multi-
disciplinary team and the ethical concerns of relying on 
ANN in making such life changing and expensive deci-
sion. The utility analysis of  those ES would have been 
essential for tailoring their development for real time 
applications where they can be more substantial to the 
user. One example is lack of community-based systems 
for the initial referral of suspected cancer patients and 
follow up of stable disease, where NICE have identified a 
need for such decision support models [152, 153].
There was a wide diversity of modelling in Urologi-
cal ES with ANN being the most common model in this 
review. These would bypass the need for direct learning 
from experts and the exhaustive process of knowledge 
acquisition, which is a core requirement for knowledge-
based systems to attest the whole system progress [55]. 
However, their analytical hidden layer of nodes “black 
box phenomenon” has been a subject for wide criticism 
and rejection from clinicians due to lack of transparency 
and understanding of its function.
Stephan et  al. suggested a statistical solution to iden-
tify the variables significance by performing sensitivity 
analysis [154]. This estimates the variation of the AUC 
with introduction or elimination of each variable. This 
can only reflect the significance of each variable but does 
not explain how the cases are being solved nor quantify 
this to the user in a standard statistical value. This can 
be useful in research as they can identify significant vari-
ables in a large set data and has been successfully applied 
in the field of academic urology as in [119] where the sys-
tem successfully identified the relevant gene signature for 
bladder cancer progression which saved time and cost of 
microarray analysis of all suspected genes.
Holzinger et al. emphasised on the importance of the 
explicability of the AI model specially in medicine which 
is a clear challenge for machine learning due to their com-
plex reasoning [155]. Their study attempted to simplify 
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Table 9 Qualitative assessment of urological Expert Systems
Art Mdl Validation methods Credibility Evaluation Validation Verification Strength and bias
[27] RBR Patients’ evaluation No Yes Yes No Only qualitative evaluation
[18] RBR Blinded comparison against 4 experts 
with independent experts rating 
and 3 centres RCT pilot trial
Yes Yes Yes No Consideration of system evaluation with 
real time testing but small number
[21] FRB Improve practitioner accuracy No No No No Insufficient info on development and 
validation
[15] RBR RCT reliability and validity by experts’ 
reviews
Yes Yes Yes No Small number in the study and short 
duration of follow up
[95] ANN ROC, Sp, Se No No Yes No Small number for validation
[63] FSS ROC, Sp, Se No No Yes No 2 methods for validation, compared to 
experts and data
[143] ANN Compare to histology results No No Yes No No comparison to human to demon-
strate usability, no p value or CI
[103] FNM ROC, LR, RMS No No Yes No p value calculated to compare all 
models
[103] ANN ROC, LR, RMS No No Yes No p value calculated to compare all mod-
els, the effect of combining HK p53 
with other variables
[102] ANN ROC, Sp, Se No No Yes No No p value
[76] ANN Correlation co-efficient No No Yes No Correlation co-efficient between expert 
and system? Kappa more accurate
[40] FRB Not published No No No No Not validated
[68] ANN AUC ROC No No Yes No p value calculated vs LR
[19] RBR Feedback from patients with no 
control group
No Yes No No No validation but user (patient evalu-
ation)
[29] FRB Comparison to experts and non-
experts
No No Yes No Expert as gold standard
[25] RBR PPV 62%, NPV 100%
Se 100% Sp 33%
No No Yes No Small number, low specificity
[55] ANN ROC AUC then compare with LR, 
kappa stats
No No Yes No Multimodal of validation
[99] ANN ROC, Sp, Se No No Yes No Not long term follows up
[43] ANN ROC (0.74 and 0.86) No No Yes No TRUS finding from expert panel, human 
as gold standard
[105] FNM ROC, LR No No Yes No p value calculated to compare all 
models
[105] ANN Kaplan Maier for survival No No Yes No p for comparison ANN and FNM 
calculated
[145] kNN Comparison to other classifiers and 
ROC
No Yes Yes No Evaluated the usability of the product 
and was found to have less than 
significant effect
[129] ANN ROC Se, Sp No No Yes No Sensitivity analysis of input variables
[22] ANN ROC 0.7, accuracy 79% No No Yes No Compare to experts without accounting 
for human error
[85] FRB ROC Se, Sp No No Yes No No user evaluation
[24] FRB Ac 0.76, Se 0.79, Sp 0.75 No No Yes No Expert as gold standard
[109] ANN ROC Compare to LR No No Yes No CI calculated
[12] FRB Ac 0.93, Se 0.97, Sp 0.99 No No Yes No Expert as gold standard
[110] ANN Prediction error percent No No Yes No Experimental results
[48] SVM ROC AUC No No Yes No P value calculated to compare all 
models
[146] ANN Overlap measure (segmented by 
experts)
No No Yes No Expert as gold standard
[23] ANN Ac 0.84, Se 0.93, Sp 0.33 No No Yes No Experts verified data no account for 
human error
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All systems’ development was qualitatively assessed against the common industrial steps in the development pathway described by Okeefe and Benbasat. With 
exception of the system validation, the rest of the cycle was defective with no explanation. The validation had variable degree of strength with common application of 
the receiver operator characteristic for estimating the area under the curve for data driven systems
Table 9 (continued)
Art Mdl Validation methods Credibility Evaluation Validation Verification Strength and bias
[30] FNM Accuracy 86.8% No No Yes No Guidelines as gold standard





Kappa vs experts, k = 0.89 No No Yes No Kappa limitation prospective, randomi-
sation,
[16] RBR Se 0.95, Sp 0.72, Bayesian analysis S&S, 
usability of system by Likert scale 
(Cronbach’s alpha 0.9)
Yes Yes Yes No Full system evaluation but nurse as gold 
standard, no attempts to eliminate 
error
[91] ANN ROC AUC compare with Partin nomo-
gram and LR
No No Yes No No correlation with user
[17] FNM Kappa vs experts, Se 0.95, Sp 0.92 No No Yes No Human expert as gold standard and no 
qualitative evaluation (weight of error)
[60] ANN Ac 60% (testing) 75% (training) No No Yes No Compare to gold standard, Urodynamic
[117] ANN PPV 100% No No Yes No No calculation of NPP and overall 
accuracy
[32] FNM Correlation coefficient = 0.99 No No Yes No Small number of cases for validation
[150] FCM OR 86.3% No No Yes No Comparison with experts as gold stand-
ard than mapping to histology
[141] ANN ROC, Se 64.2%, Sp 59.6%, PPV 61.6%, 
NPV 62.2%, AUC 0.6852
No No Yes No Similar to urodynamic as research tool
[54] FRB None No No Yes No No validation
the explanation by classifying the systems into post-hoc 
or ante-hoc. In post-hoc, explanations were provided for 
a specific decision as in model agnostic framework where 
the black box reasoning can be explained through trans-
parent approximations of the mathematical models and 
variable [156, 157]. Those are reproduced on demand for 
a specific problem rather than the whole system which 
can shed more light on the system function. It is not cer-
tain if those can be easily interpreted by the AI novice 
clinician, but it has provided more explicit models for 
tackling the black box phenomenon.
Knowledge based systems can be explained by ante 
hoc models where the whole system reasoning can be 
represented. Those systems rely on expert knowledge 
in their development and face the bottle neck phenom-
enon in their applications. Furthermore, they are not 
always successful in identifying and mapping multilin-
ear mathematical rules and machine learning is man-
datory or at least more efficient [155]. Bologna and 
Hayashi et al. suggested that machine learning is more 
successful in complex problem solving with inverse 
relation between the machine performance, and it is 
built-in transparency [158].
Another common aspect lacking in these articles was 
the coupling of their system development methodology 
with the medical device registration requirements. This 
is essential as ES often function as standalone software 
with no human supervision to their calculation. This 
categorises the system as a medical device with man-
datory perquisite to register with the relevant authori-
ties as Medicines & Healthcare products Regulatory 
Agency in the UK [5].
Cabitza et al. compared AI validation to other medical 
interventions as drugs and emphasised on considering 
the “software as a medical device” [159]. Unlike other 
devices or drugs, AI models in healthcare are unique 
in being more dynamic which should be reflected in 
their validation cycle. They also quoted the known term 
“techno-vigilance” to learn from other medical device 
validation pathways. They recommended different out-
look to validation where it is broken down to statistical 
(efficacy), relational (usability), pragmatic (effective-
ness) and ecological (cost-effectiveness) with available 
standards for those steps (ISO 5725, ISO 9241 and ISO 
14155). The latter is viewed as a novel standard for eval-
uating the cost benefits of applying specific AI model 
in healthcare which would require longitudinal mod-
elling of health economics [159]. This was evidently 
lacking in articles that were included in our review and 
in fact most of the studies were non-randomised and 
retrospective.
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Similarly, Nagendran et  al. systematically analysed 
studies that compare AI performance to experts in clas-
sifying medical imaging into diseased and non-diseased, 
they concluded that AI performance was non-inferior 
to human experts with potential for out-performing 
[160]. Their 10  years review identified from literature 2 
randomised clinical trials and 9 prospective non-ran-
domised trials extracted from a total of 10 and 81 studies, 
respectively. Their review assessed the risk of bias using 
PROBAST (prediction model risk of bias assessment 
tool) criteria for non-randomised studies. The tool is 
designed for identifying the risk of bias by analysing four 
domains (participant, predictors, outcome, and analysis) 
[161], which is applicable to systematic review analysing 
prediction model with a target outcome.
In our study,  as there was no unified outcome for the 
included prediction tools, the scope was on the role of 
validation rather than the outcome.  Therefore, those 
tools assessing the risk of bias were not utilised due to 
the wide gaps in the tool checklist between the included 
articles. Such study design and data heterogeneities were 
also evident in Nagendran et al. and similar to our study, 
data synthesis was not possible. This will pose a chal-
lenge reinforcing the application of AI models in health-
care due to lack of level 1 evidence which is mandatory in 
healthcare for accepting a novel intervention.
Finally, the quality of the data analysis was beyond the 
scope of our systematic review despite being essential 
for developing quality AI systems. Cabitza et  al. exam-
ined this gap and focused on the data governance [161]. 
There has been very limited evidence on data quality 
appraisal and standards with call for further research 
and allocation of more resources specially in healthcare 
where the data are notoriously limited with errors or 
discordance.
The potential application of AI in urology with focus on 
its future application has been recently discussed by Emi-
naga et al. [162]. They have shown an increasing interest 
in urology research, but with a challenged mechanistic 
update due to the model complexity and lack of end user 
understanding of its design and function. Furthermore, 
they identified discrepancy between AI engineering and 
clinical application which reflects some lack of communi-
cation between both disciplines.
This can be either a consequence or a cause for lack 
of clinical utility testing, which increases the need for 
research in this domain to be incorporated in the soft-
ware development  [163]. In fact, it has been recom-
mended to perform the utility test before developing the 
system to tailor its application [164, 165]. Despite hav-
ing different methodology to our systematic review, the 
recommendations were similar with strong emphasis on 
the lack of utility testing and its impact on AI uptake in 
healthcare [166–168].
Conclusion
ES have been advancing in Urology with demonstrated 
versatility and efficacy. They have suffered from lack of 
formality in their development, testing and methodology 
for registration, which has limited their uptake. Future 
research is recommended in identifying criteria for suc-
cessful functional domain applications, knowledge engi-
neering and integrating the system development with the 
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Expert systems
Fig. 4 Expert System (ES) analysis by year of publication showing an upward trend and increase in number of publications. Systems were included 
according to the keywords for expert system models and applied in urological domains
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registration requirement for their future implementation 
in the health care systems.
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